AffiliationAdelaide and Meath Hospital, Incorporating the National Children's Hospital,, Tallaght, Trinity College Dublin, Ireland. firstname.lastname@example.org
*Antacids/administration & dosage/adverse effects/therapeutic use
*Anti-Bacterial Agents/administration & dosage/adverse effects
Anti-Ulcer Agents/administration & dosage/adverse effects/therapeutic use
*Bismuth/administration & dosage/adverse effects/therapeutic use
*Capsules/administration & dosage/adverse effects/therapeutic use
Drug Administration Schedule
Drug Therapy, Combination
Helicobacter Infections/*drug therapy/microbiology
Helicobacter pylori/*drug effects
*Metronidazole/administration & dosage/adverse effects/therapeutic use
Omeprazole/administration & dosage/adverse effects/therapeutic use
Randomized Controlled Trials as Topic
*Tetracycline/administration & dosage/adverse effects/therapeutic use
MetadataShow full item record
CitationExpert Rev Anti Infect Ther. 2009 Sep;7(7):793-9.
JournalExpert review of anti-infective therapy
AbstractAn ideal antibiotic regimen for Helicobacter pylori should achieve eradication rates of approximately 90%. Current 7-day triple therapy is successful in about two-thirds of patients. A novel treatment is required to achieve higher eradication with minimal induction of bacterial resistance. The aim of this article is to evaluate the safety and efficacy of a single triple capsule (Pylera) containing bismuth, metronidazole and tetracycline, given with omeprazole for the eradication of H. pylori infection. Extensive literature searches were conducted using PubMed data from 1982 to 2007. This search included headings of H. pylori, bismuth and eradication therapy. The triple capsule Pylera, when given with omeprazole, achieved eradication rates ranging between 84 and 97%. Eradication rates were similar for clarithromycin- and metronidazole-resistant strains. Eradication rates with an omeprazole, bismuth, metronidazole and tetracycline regimen appeared comparable for metronidazole-resistant and -sensitive strains. This effect is not seen with the use of triple therapy in cases of clarithromycin resistance. Clinical trials did not report any serious side effects from bismuth-based regimens and compliance was similar to standard triple therapy. Bismuth-based triple therapy using Pylera is a simplified, effective and well-tolerated regimen achieving cure rates of above 90%.
- The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
- Authors: Bago J, Halle ZB, Strinić D, Kućisec N, Jandrić D, Bevanda M, Tomić M, Bilić A
- Issue date: 2002 Jun 28
- A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
- Authors: Lerang F, Moum B, Ragnhildstveit E, Haug JB, Hauge T, Tolås P, Aubert E, Henriksen M, Efskind PS, Nicolaysen K, Søberg T, Odegaard A, Berge T
- Issue date: 1997 Apr
- One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
- Authors: Kung NN, Sung JJ, Yuen NW, Li TH, Ng PW, Lai WM, Lui YH, Lam KN, Choi CH, Leung EM
- Issue date: 1999 Mar
- Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
- Authors: Kung NN, Sung JJ, Yuen NW, Ng PW, Wong KC, Chung EC, Lim BH, Choi CH, Li TH, Ma HC, Kwok SP
- Issue date: 1997 Mar
- Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
- Authors: Vakil N, Fennerty MB
- Issue date: 1996 Feb